



eTable 1 Demographic and diseases characteristics of patients in PCSK-9 inhibitor and statins group before matched

	Statins N=2610	PCSK-9 inhibitor (n=453)	P value
Age, median (IQR)	59(52, 65)	60(51, 68)	0.510
Male gender, n (%)	620(23.8%)	311(68.7%)	<0.001
Body Mass Index, median(IQR)	25.71(23.72, 27.78)	24.78(23.29, 26.53)	<0.001
Hypertension, n(%)	1521(58.3%)	302(66.7%)	0.001
Diabetes, n(%)	730(28.0%)	125(27.6%)	0.869
Stroke (%)	172(6.6%)	61(13.5%)	<0.001
Chronic Kidney Disease, n(%)	19(0.7%)	7(1.5%)	0.80
Smoke, n(%)	1315(50.4%)	216(47.7%)	0.289
Medical history			
MI	225(8.6%)	123(27.2%)	<0.001
PCI	316(12.1%)	90(19.9%)	<0.001
CABG	26(1.0%)	44(9.7%)	<0.001
Inpatient diagnose			<0.001
Stable angina	231(8.9%)	25(5.5%)	0.018
Unstable angina	1589(60.9%)	274(60.5%)	0.844
NSTEMI	494(18.9%)	66(14.6%)	0.026
STEMI	292(11.2%)	80(17.7%)	<0.001
Ischemic cardiomyopathy	4(0.2%)	8(1.8%)	<0.001
Lab test			
LDL (mmol/L), median(IQR)	2.31(1.78, 2.97)	3.04(2.16, 4.00)	<0.001
HDL(mmol/L), median(IQR)	0.97(0.82, 1.14)	1.08(0.92, 1.28)	<0.001
TC (mmol/L), median(IQR)	3.90(3.30, 4.70)	4.97(3.95, 6.04)	<0.001
TG (mmol/L), median(IQR)	1.45(1.04, 2.01)	1.97(1.24, 3.09)	<0.001

MI:myocardial infarction; PCI: percutaneous coronary intervention; CABG:coronary artery bypass graft; NSTEMI:non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TC: total cholesterol; TG: Triglyceride;



eFigure 1 The overall patient treated with statins and goal LDL-c Level in the real world.



efigure 2. Patients' flow chart